These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20379178)

  • 1. RNA interference in three humans.
    Hare P
    Nat Biotechnol; 2010 Apr; 28(4):335. PubMed ID: 20379178
    [No Abstract]   [Full Text] [Related]  

  • 2. The promises and pitfalls of RNA-interference-based therapeutics.
    Castanotto D; Rossi JJ
    Nature; 2009 Jan; 457(7228):426-33. PubMed ID: 19158789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interfering with disease: opportunities and roadblocks to harnessing RNA interference.
    Lieberman J; Song E; Lee SK; Shankar P
    Trends Mol Med; 2003 Sep; 9(9):397-403. PubMed ID: 13129706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Companies in footrace to deliver RNAi.
    Bouchie A
    Nat Biotechnol; 2012 Dec; 30(12):1154-7. PubMed ID: 23222766
    [No Abstract]   [Full Text] [Related]  

  • 5. RNA interference: Homing in on delivery.
    Baker M
    Nature; 2010 Apr; 464(7292):1225-8. PubMed ID: 20414308
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.
    Deng Y; Wang CC; Choy KW; Du Q; Chen J; Wang Q; Li L; Chung TK; Tang T
    Gene; 2014 Apr; 538(2):217-27. PubMed ID: 24406620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug research. Roche exits RNAi field, cuts 4800 jobs.
    Couzin-Frankel J
    Science; 2010 Nov; 330(6008):1163. PubMed ID: 21109638
    [No Abstract]   [Full Text] [Related]  

  • 8. Journey of siRNA: Clinical Developments and Targeted Delivery.
    Nikam RR; Gore KR
    Nucleic Acid Ther; 2018 Aug; 28(4):209-224. PubMed ID: 29584585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
    Hovingh GK; Lepor NE; Kallend D; Stoekenbroek RM; Wijngaard PLJ; Raal FJ
    Circulation; 2020 Jun; 141(22):1829-1831. PubMed ID: 32479195
    [No Abstract]   [Full Text] [Related]  

  • 10. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
    de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA interference: an emerging generation of biologicals.
    Shrivastava N; Srivastava A
    Biotechnol J; 2008 Mar; 3(3):339-53. PubMed ID: 18320564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy.
    Tsao CK; Oh WK
    Asian J Androl; 2011 Mar; 13(2):181-2. PubMed ID: 21076441
    [No Abstract]   [Full Text] [Related]  

  • 13. Innovations in siRNA research: a technology comes of age.
    Hefferon KL
    Recent Pat Antiinfect Drug Discov; 2010 Nov; 5(3):226-39. PubMed ID: 20812899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycation-based nanoparticle delivery for improved RNA interference therapeutics.
    Howard KA; Kjems J
    Expert Opin Biol Ther; 2007 Dec; 7(12):1811-22. PubMed ID: 18034647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA interference: From tools to therapies.
    Baker M
    Nature; 2010 Apr; 464(7292):1225. PubMed ID: 20414309
    [No Abstract]   [Full Text] [Related]  

  • 16. [Present and future of ribonucleic acid interference].
    Pinazo-Durán MD; Zanón-Moreno V; Vinuesa Silva I; García Medina JJ; Benítez del Castillo J
    Arch Soc Esp Oftalmol; 2015 Jan; 90(1):1-3. PubMed ID: 25660458
    [No Abstract]   [Full Text] [Related]  

  • 17. RNA-interference-based gene therapy approaches to HIV type-1 treatment: tackling the hurdles from bench to bedside.
    von Eije KJ; Berkhout B
    Antivir Chem Chemother; 2009; 19(6):221-33. PubMed ID: 19641231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
    Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular medicine for the brain: silencing of disease genes with RNA interference.
    Davidson BL; Paulson HL
    Lancet Neurol; 2004 Mar; 3(3):145-9. PubMed ID: 14980529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on RNA interference-mediated gene silencing in cancer therapy.
    Ren YJ; Zhang Y
    Expert Opin Biol Ther; 2014 Nov; 14(11):1581-92. PubMed ID: 25010067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.